Critically, MPS2 had 99% sensitivity and 99% NPV for cancers of GG 3 or greater, meaning the rare false-negative MPS2 results were almost uniformly more favorable cancers of GG 2 least likely to metastasize. This evidence concerns the gene IDS and cancer.